A *Toxoplasma gondii* locus required for the direct manipulation of host mitochondria has maintained multiple ancestral functions

Matthew L. Blank ^{(D),1} Michelle L. Parker,^{2†‡} Raghavendran Ramaswamy,^{2†} Cameron J. Powell,² Elizabeth D. English,^{1§} Yaw Adomako-Ankomah,^{1¶} Lena F. Pernas,^{3#} Sean D. Workman,² John C. Boothroyd,³ Martin J. Boulanger^{2*} and Jon P. Boyle^{1**}

¹Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA.

²Department of Biochemistry and Microbiology,

University of Victoria, Victoria, BC, Canada.

³Department of Microbiology and Immunology,

Stanford University School of Medicine, Stanford, CA, USA.

Summary

The Toxoplasma gondii locus mitochondrial association factor 1 (MAF1) encodes multiple paralogs, some of which mediate host mitochondrial association (HMA). Previous work showed that HMA was a trait that arose in T. gondii through neofunctionalization of an ancestral MAF1 ortholog. Structural analysis of HMA-competent and incompetent MAF1 paralogs (MAF1b and MAF1a, respectively) revealed that both paralogs harbor an ADP ribose binding macro-domain, with comparatively low (micromolar) affinity for ADP ribose. Replacing the 16 C-terminal residues of MAF1b with those of MAF1a abrogated HMA, and we also show that only three residues in the C-terminal helix are required for MAF1-mediated HMA. Importantly these same three residues are also required for the in vivo growth advantage conferred by MAF1b, providing a definitive

Accepted 1 March, 2018. For correspondence. *E-mail mboulang@ uvic.ca; Tel. (+1) 250 721 7072. **E-mail boylej@pitt.edu; Tel. (+1) 412 624 5842; Fax (+1) 412 624 4759. †These authors contributed equally to this work. Present addresses: [†]Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada [§]Department of Pathobiology, University of Pennsylvania, Philadelphia, PA, USA [¶]National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA ^{††}Department of Biology, University of Padova, Padova, Italy

© 2018 John Wiley & Sons Ltd

link between *in vivo* proliferation and manipulation of host mitochondria. Co-immunoprecipitation assays reveal that the ability to interact with the mitochondrial MICOS complex is shared by HMA-competent and incompetent MAF1 paralogs and mutants. The weak ADPr coordination and ability to interact with the MICOS complex shared between divergent paralogs may represent modular ancestral functions for this tandemly expanded and diversified *T. gondii* locus.

Introduction

Tight associations between pathogen-containing vacuoles and host organelles such as mitochondria have been described in a variety of intracellular pathogens, including Chlamydia psittaci (Matsumoto et al., 1991), Legionella pneumophila (Horwitz, 1983), Hammondia hammondi (Adomako-Ankomah et al., 2016) and Toxoplasma gondii (Jones et al., 1972; Sinai et al., 1997; Pernas et al., 2014). While these phenotypes have been known for decades, the underlying molecular mechanisms are poorly understood. In most cases, the pathogen molecules required for organellar association have not been identified, or have their cognate binding partners in the host. This has hindered our ability to understand the relevance of this intimate association between the pathogen-containing vacuole and the host mitochondrion to infection outcome.

In *T. gondii*, we and others have identified the parasite locus that is required for host mitochondrial association (HMA), *mitochondrial association factor 1B (MAF1b)* and shown that expression of MAF1b increases cytokine signaling (Pernas *et al.*, 2014) during the acute phase of *in vivo* infections. In infected cell lysates and cells expressing MAF1b ectopically, MAF1b protein interacts with host mitochondrial outer membrane proteins belonging to the MICOS complex, which may be involved in the ability of MAF1b to mediate HMA (Kelly *et al.*, 2017). During the acute phase of mouse infections, MAF1b-expressing parasites outcompete their MAF1b-null counterparts (Adomako-Ankomah *et al.*,

2016), implying that MAF1b plays an important role in determining infection outcome.

The *T. gondii* MAF1 locus encodes multiple tandemly duplicated paralogs that vary both in sequence and copy number across T. gondii strains (Adomako-Ankomah et al., 2014, 2016). TgMAF1 paralogs fall into two broad groups, which we have defined as 'A' and 'B' based on residue percent identity (Adomako-Ankomah et al., 2016). All nonpseudogenized MAF1 genes sequenced to date contain a signal peptide, a transmembrane (TM) domain and a large C-terminal region that lacks identifiable sequence homology to any known proteins (Fig. 1A) (Pernas et al., 2014; Adomako-Ankomah et al., 2016). MAF1 paralogs harbor a repetitive, proline-rich region between the puta-TM and C-terminal region that broadly tive distinguishes the 'A' and 'B' paralog groups. In genetic complementation experiments, only MAF1b paralogs are capable of complementing HMA⁽⁻⁾ Type II strains, while complementation with MAF1a has no effect on HMA (Adomako-Ankomah et al., 2016). Numerous polymorphisms further distinguish TgMAF1RHa1 and TgMAF1RHb1, including in the C-terminus, which is more divergent across paralogs compared to the Nterminus (Adomako-Ankomah et al., 2016). Since MAF1b paralogs are present only in those species that are capable of mediating HMA and all other strains only harbor MAF1 paralogs most similar to the nonfunctional 'A' copies, we hypothesized that the ability of MAF1b to intimately interact with host mitochondria evolved by neofunctionalization of an ancestral version of MAF1. While the ancestral role of MAF1a has yet to be determined, these nonfunctional (with respect to HMA) ancestral paralogs represent a robust comparative tool to further probe the mechanism, and ultimately the function, of HMA in T. gondii.

In the present study, we first determined the overall structures of representative members of the A and B paralog groups using X-ray crystallography. These data allowed us to map the detailed structural differences between the A and B paralogs and identify specific residues within the C-terminal helix of MAF1a and MAF1b, that through mutagenesis studies, we showed are required for MAF1b to mediate HMA. We further leveraged these mutants to provide the first direct evidence that the C-terminus of a MAF1b paralog is essential, not only to HMA itself, but to the in vivo selective advantage conferred by HMA⁽⁺⁾ T. gondii. We have also uncovered two putative ancestral functions for the MAF1 gene family that are shared by MAF1a and MAF1b paralogs, providing further support for the theory that mitochondrial association arose in T. gondii via neofunctionalization of an ancestral version of MAF1.

Results

The TgMAF1RHb1-specific proline-rich domain is dispensable for MAF1 function in HMA

Type II T. gondii strains (including TgME49 and PRU) are HMA negative and express undetectable levels of TgMAF1RHb1 (Adomako-Ankomah et al., 2016). Complementation of ToME49 and the near relative Neospora caninum, with TqMAF1RHb1 but not TqMAF1RHa1, confers the HMA phenotype (Adomako-Ankomah et al., 2016). To identify regions of ToMAF1RHb1 that are required for HMA, we pursued a hypothesis-driven approach by comparing all sequenced MAF1 paralogs (Adomako-Ankomah et al., 2016). Sequences were aligned using Clustal-Omega and visualized in JalView (Fig. 1A). Consistent with previous observations, the sequences cluster into two main groups (Adomako-Ankomah et al., 2016), distinguished by the absence ('A' group) or presence ('B' group) of a proline-rich stretch between the putative TM and the C-terminal region. To investigate the significance of the prolines in this region of TaMAF1RHb1, prolines 152-157 and 159-164 were mutated to alanine residues. However, these mutant paralogs were still capable of complementing HMA in TgMe49 parasites (Fig. 1B). In an effort to disrupt the proline-rich region using an alignment-guided approach, separate mutations were made to the region flanking either side of the proline-rich region. Additionally, a third construct was made where the entirety of the proline-rich region, residues 131-174, was replaced with the aligned sequence in TqMAF1RHb0 (HMA⁽⁻⁾), which is nearly identical to TgMAF1RHa1 in this region (Fig. 1A). Consistent with our point mutation analyses, this particular chimeric construct was still capable of mediating HMA in T. gondii strain TgME49 (Fig. 1C). Additionally, work investigating the phosphoproteome following T. gondii infection identified significant MAF1 phosphorylation after secretion into the host cell (Treeck et al., 2011). To test the role of possible phosphorylation of the serines found within the MAF1b-specific prolinerich region, we mutated TgMAF1RHb1 serine 158 to alanine. This mutation did not disrupt the ability of TgMAF1RHb1 to confer HMA in TgMe49 parasites (Fig. 1B). Overall, these data demonstrate that the prolinerich region is dispensable for HMA, despite its presence in all functional MAF1b paralogs.

The C-terminal regions of both TgMAF1Rha1 and b1 adopt an α/β globular structure with homology to ADP-ribose binding macro-domains

Aside from the proline-rich region characteristic of *Tg*MAF1RHb1 paralogs, there are no other N-terminal

Α		100%	Percent Identity	0%
HhMAF1a1 IMWR V CK S K LY F LF A A C L L G A L TAG L C S U I S C A G K N VQ A P A G V A D A P Q E A G D V V E F TgMAF1RHa1 IMWR LW CK S F LF A T C L L G A L TAG L C S W S D S V C R N VQ A P A G V A D A S Q E A G D V V E F TgMAF1RH40 IMWR LW C R S F LF A T C L L G A L TAG L C S W S D S V C R N VQ A P A G V A D A S Q E A G D V V E F TgMAF1Me49b0 IMWR LW C R S F LF A T C L L G A L TAG L C S W S D S V C R N VQ A P A G V A D A S Q E A G D V V E F HMAF1Hb1 I W R V C K S S L Y L F TA G C L L G A L TAG L C S W S D S V C R N VQ A P A G V A D A S Q E A G D V V E F TgMAF1Me49b1 I W R I W C K S S L Y L F TA G C L L G A L TAG L S G W S D S V C R N VQ A P A G V A D A S Q E A G D V V E F TgMAF1Me49b1 I W R I W R C K S S L Y L F TA T C C L L G A L TAG L S G W S D V C R N VQ A P A G V A D A S Q E A G D V V E F TgMAF1CTGb1 I W R I W C C S L S L F A T C C L L G A L TAG L S G W S D V C R N VQ A P A G V A D A S Q E A G D V V E F TgMAF1CTGb2 I W R I W R C K S L F L F A T G C L L G A L TAG L S G W S D V C R N VQ A P A G V A D A S Q E A G D V V E F TgMAF1RH1 I W R I W R C K L S L F A T G C L L G A L TAG L S G W S D V C R N VQ A P A G V A D A S Q E A G D V V E F TgMAF1RH5 I W R I W R C K L S F L F A T G C L L G A L TAG L S G W S D V C R N VQ A P A G V A D A S Q E A G D V V E F TgMAF1RH5 I W R I W R C K L S F L F A T G C L L G A L TAG L S G W S D V C R N VQ A P A G V A D A S Q E A G D V V E F <		P R SP S V T A R R R N P R NP S V T A R R R R P R NP S V T A R R R R P R NP S V T A R R R R P R NP S V T A R R R R P R NP S V T A R R R R P R NP S V T A R R R R P R NP S V T A R R R R P R NP S V T A R R R R P R NP S V T S R R R R R P R NP S V T S R R R R N P R NP S V T S R R R R N P R NP S V T S R R R R N P R NP S V T S R R R R N	RR I A LV AT AV GVAV V EAA LY RR I AP I AT AV GVAV I EAA LY RR I AP I AT AV GVAV I EAA LY RR I ALI AT AV GVAV I EAA LY RR I ALV AT AV GVAV I EAA LY RR I ALVAT AV GVAV I EAA LY RR I ALI AT AV GVAV I EAA LY	Y L R 11 Y L R 11
	B1	ß2	β	3
HhMAF1a1 118 K.W.W.R.P.P.E.E.P.E.P.T.R.P.R.T.R.F.T.T.P.S.CQ. QQ.P.S.P.G.R.P. TgMAFFIRHa1 118 R.R.Q.P.Q.E.E.P.T.R.R.T.R.P.R.P.A.P.S.CQ. QQ.P.S.E.G.P. TgMAFFIRHa1 118 R.R.Q.P.Q.E.E.P.T.R.R.T.R.P.R.P.A.P.S.CQ. QQ.P.S.E.G.P. TgMAFFIRHa1 118 R.W.Q.P.Q.E.E.P.T.R.R.T.R.P.R.P.A.P.S.CQ. QQ.P.S.E.G.P. TgMAFFIRHa1 118 R.W.Q.P.Q.E.E.P.T.R.R.T.R.P.R.P.A.P.S.CQ. QQ.P.S.E.G.P. TgMAFFIRHa1 118 R.W.Q.P.Q.D.E.E.P.T.R.R.T.R.P.R.P.A.P.S.CQ. QQ.P.S.E.G.P. TgMAFFIRHa1 118 R.W.Q.P.Q.D.E.E.P.T.R.R.T.R.P.R.P.A.P.S.CQ. QQ.P.S.E.G.P. TgMAFICTGD2 118 R.W.Q.P.Q.D.E.E.P.T.R.R.P.R.P.S.CD.D.P.S.L.D.F.S.S.L.P.P.P.P.F.S.P.P.P.S.P.P.P.S. TgMAFFICTGD2 118 R.W.Q.P.Q.D.E.E.P.T.R.S.W.D.P.E.V.LP.E.D.E.A.S.S.L.V.P.P.P.F.S.P.P.P.S.P.P.P.S.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.S.P.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.P.S.P.P.P.S.P.P.S.P.P.P.S.P.P.S.P.P.S.P.	A G V W A V W G S L T L R L A E V W Y T D P U T L R Y A G V W K Y G S L T L P A G V W K Y G S L T L P P P P P V E E V L S E S G Y V O L P P P P Y V E V L S E S G Y V O L P P P P Y V E V L S E S G Y V O L P P P P Y V E V L S E S G Y V O L P Y E D L S E S G Y V O L P Y E D L S E S G Y V O L P Y E D L S E S G Y V O L P Y E D L S E S G Y V O L P Y E D L S E S G Y V O L P Y E D L S E S G Y V O L P Y E D L S E S G Y V O L	T CL R DT E VK F G P T CL GD R N I F F G P T CL GD R N T F F G P S CL S GT T N F F G P S CL S GT T N F F G P S CL S GT T N F F G P S CL S GT T N F F G P S CL S GT T N F F G P S CL S GT T N F F G P	S S H R H G F T P L Y D P V A N K R V A S G R Q D G F T P L Y D P S P S R N A S G R Q H G T T L Y D P S P S R N A S G R Q H G T T L Y D P S P N R N A S H P G G T T L Y D A P D R N A S H S G G T T L Y D A P D R N A S H F G G T T P Y D A P D R N A S H F G G T T L Y D A P D R N A S H F G G T T L Y D A P D R N A S H F G G T T L Y D A P D R N A	A T V N20 A T V D20 A T V D20 A T V D20 A T V D22 A T V D23 A T V D21 A T V D21 A T V D21
α1 α2	β4 β 5		β6	
HhMAF1a1 204 A G T N T L F L G G S M N E F A K L I F E A R R N H I S L TA A E L S A H S G E L G E R L R D A E R P G S TGMAFIRHa1 204 A G T Y L F L G G S M N E F A D L I F E A R R N H I S L TA A E L S A H S G E L G E R L I R D A E R P G S TGMAFIRHA1 204 A G T Y C L F L G G C I N G F A T L L E A R R N H I S L TA A E L S A H S G E L G E R L I R D A E R P G S TGMAFIRHA1 204 A G T Y C L F L G G C I N G F A T L L E A E R NG I R T S Y A L S E H S G R I Q S L I R A V K S P G K TGMAFIRHA1 204 A G A N A L F I G G G L N G F A T L L E A E K NG I R T S Y A L S E H S G R I Q S L I R A V K S P G K TGMAFIRHA1 225 A G A N A L F I G G G L N G F A T L L E A E K NG I R T S Y A L S E H S G R I Q S L I R A V K S P G K TGMAFINHO1 225 A G A N A L F I G G G L N G F A T L L E A E K NG I R T F E L S E H S G R I Q S L I R A V K S P G K TGMAFINHO1 225 A G A N A L F I G G G L N G F A T L L E A E K N G I R T F E L S E H S G R I Q S L I R A V K S P G K TGMAFINHO2 226 A G A N A L F I G G G L N G F A T L L E A E K N G I R T F E L S S H S G I Q S L I R A V K S P G K TGMAFINHO2 225 A G A N A L F I G G G L N G F A T L L E A E K H G I R T F E L S S H S G I Q S L I R A V K S P G K TGMAFINHO2 225 A G A N A L F I G G G L N G F A T L L E A E K H G I R T F E L S Q H S G R Q S L I R A V K S P G K TGMAFINHO2 220	$\label{eq:constraint} \begin{array}{c} \textbf{U} \in \textbf{I} \ \textbf{D} \ \textbf{S} \ \textbf{C} \ \textbf{S} \ \textbf{F} \ \textbf{P} \ \textbf{V} \ \textbf{F} \ \textbf{a} \ \textbf{R} \ \textbf{S} \ \textbf{A} \ \textbf{F} \ \textbf{A} \ \textbf{P} \ \textbf{V} \ \textbf{A} \\ \textbf{V} \ \textbf{V} \ \textbf{L} \ \textbf{D} \ \textbf{G} \ \textbf{C} \ \textbf{R} \ \textbf{S} \ \textbf{F} \ \textbf{A} \ \textbf{F} \ \textbf{A} \ \textbf{S} \ \textbf{G} \ \textbf{V} \ \textbf{V} \\ \textbf{V} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{D} \ \textbf{G} \ \textbf{C} \ \textbf{R} \ \textbf{S} \ \textbf{F} \ \textbf{A} \ \textbf{S} \ \textbf{R} \ \textbf{S} \ \textbf{G} \ \textbf{V} \ \textbf{V} \\ \textbf{V} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{C} \ \textbf{A} \ \textbf{V} \ \textbf{A} \ \textbf{V} \ \textbf{P} \ \textbf{A} \ \textbf{S} \ \textbf{G} \ \textbf{V} \ \textbf{V} \\ \textbf{V} \ \textbf{U} \ \textbf{A} \ \textbf{V} \ \textbf{A} \ \textbf{V} \ \textbf{A} \ \textbf{V} \ \textbf{A} \ \textbf{V} \ \textbf{V} \\ \textbf{V} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{U} \ \textbf{A} \ \textbf{A} \ \textbf{A} \ \textbf{A} \ \textbf{V} \ \textbf{A} \ \textbf$	S N L FW D E S E T G K N P N T VW D E S E T G K N P G L IWK K S K V G A N P G L IWK K S K V G A N P G L L WK E S E V G S N P G L IWK K S E V G S N P G L IWK E S K V G A N P G L IWK E S E V G P N P G L IWK E S E V G P N P G L IWK E S E V G P N P G L IWK E S E V G P N	Y G A A E L H I L K P E VT H G N P M Y G A T E L H I L K P E VT H G N E M Y G VT F I H I L K P E VT P Y G N E M Y G VT F I H I L K P E VT P Y G N L N Y G VT F I H I L K P E VT P Y G N L N Y G VT F I H I L K P E VT P Y G N L N Y G VT F Y H I L K P E VT P Y G N L N Y G VT F Y H I L K P E VT P Y G N L N Y G VT F Y H I L K P E VT P Y G N L N Y G VT F Y H I L K P E VT P Y G N L N Y G VT F Y H I L K P E VT P Y G N L N Y G VT F Y H I L K P E VT P Y G N L N Y G VT F Y H I L K P E VT P Y G N L N	N D V 320 N D V 320 N N V 320 N N V 341 N N V 341 N N V 351 N N V 331 N N V 336 N N V 331 N N V 336 N D V 331
	α4	89	α5	
HIMAP 1a1 321 MINT VALLENAS DAN AMMY AT MILSIVG VSKYNKT KUT KUT KUT KUT KUT KUT KUT KUT KUT K	GR 5.1 E.5 CRU TAVKT SQ GR G.1 TAVKT SQ TAVKT SQ GN S.1 E.5 RA E.7 SL TQ GN S.1 E.7 RA E.7 SL TQ GN S.1 E.7 RA E.7 SL TQ GN S.1 E.7 RA E.7 SL TQ RN I.6 RA E.7 SL T R RN		DAAFROLLUT EKFKSHOR DAARGON SRKWKFOG NAALING GASTVLASHL GAALING GASTVLASHL GAALING GASTVLASHL NAALING GASTVLASHL NAALING GASTVLASHL NAALING GASTVLASHL NAALING GASTVLASHL NAALING GASTVLASHL NAALING GASTVLASHL NAALING GASTVLASHL NAALING GASTVLASHL	D 435 D 435 D 435 D 456 D 456 D 456 D 456 D 466 D 466 D 466 D 466 D 466 D 446
P				
DiC α-HA (MAFIRHb) MitoTracker Merge	TgMAF1RHb1 (136- 144)RHa1 144)RHa1	МТСОЗ	2 Merge	
TgMAF1RH IS(158)A	TgMAF1RHb 1(170)RHb0	мтсоз	Merge	
	TgMAF1RHb1 (131- 174)RHb0	мтсоз	2 Merge	

Fig. 1. Proline-rich region of *Tg*MAF1RHb1 is not required for HMA.

A. Alignment of MAF1 isoforms from *T. gondii* and *H. hammondi* based on percent identity. Dark blue and white indicate 100 and 0% percent identity respectively. Alignments were visualized in JalView after alignment using ClustalOmega. Bold sequences refer to isoforms utilized for mutational analysis. Colored boxes correspond to the boundaries of the indicated mutation. Domain architecture is indicated above alignment and corresponds to Fig. 2B.

B. HFFs were labeled with MitoTracker and infected with *Tg*Me49 parasites expressing an HA epitope tagged *Tg*MAF1RHb1 isoform with a disrupted proline-rich domain through replacement of prolines (P) or serines (S) with alanines (A). Cells were fixed at 18 hpi and visualized by confocal microscopy.

C. HFFs were infected with TgMe49 parasites expressing an HA-tagged mutated TgMAF1RHb1 isoform. Site-directed mutations were made to the HMA⁽⁺⁾, TgMAF1RHb1 isoform to the aligned sequence in the HMA⁽⁻⁾ paralog TgMAF1RHa1 and TgMAF1RHb0. Cells were fixed at 18 hpi and visualized with confocal microscopy. Immunofluorescence staining was performed with antibodies against both the HA epitope tag and the mitochondrial protein, cytochrome *c* oxidase II (MTCO2). All mutations to the proline-rich and flanking regions were unable to disrupt TgMAF1RHb1-driven HMA.



Fig. 2. The C-terminal region of *Tg*MAF1 proteins adopts a conserved, well-ordered globular domain. A. Predicted domain architecture of *Tg*MAF1RHa1 and *Tg*MAF1RHb1. SP, signal peptide; TM, transmembrane. Colored boxes (*Tg*MAF1RHa1. deep purple; *Tg*MAF1RHb1. lime green) indicate C-terminal region with strongly predicted secondary structure elements. Numbers correspond to amino acid positions.

B. Top: tertiary structure of *Tg*MAF1RHa1 and *Tg*MAF1RHb1 colored based on secondary structure elements, with helices in cyan, strands in dark blue and loops colored as in (A). Dotted lines indicate unmolded regions and predicted features. The orientation of the proteins with respect to the parasitophorous vacuole membrane is shown. Bottom: topology diagram of *Tg*MAF1RHa1 and *Tg*MAF1RHb1 colored as in top. C. Overlay of *Tg*MAF1RHb1 (cyan) with Af1521 (dark grey; PDB ID 1HJZ) showing conservation of the core macro-domain architecture. D. Mapping of conserved (burgundy) and variable (cyan) residues of *Tg*MAF1RHa1 and *Tg*MAF1RHb1 homologs onto the *Tg*MAF1RHb1 surface using ConSurf (Ashkenazy *et al.*, 2010). The conserved cleft region is indicated in yellow.

regions in the TgMAF1 ectodomain with significant levels of polymorphism. We therefore turned our focus to the C-terminal region of the TgMAF1 ectodomain, which harbors numerous amino acid polymorphisms between the 'A' and 'B' paralog groups (e.g., TgMAF1RHb1 and TgMAF1RHa1 are 57% identical in the C-terminal region) (Fig. 1A). To best guide our approach of correlating sequence differences between TgMAF1RHa1 and TgMAF1RHb1 to their functional differences in genetic complementation, we determined the X-ray crystal structures of the C-terminal domains of TgMAF1RHb1 (Adomako-Ankomah *et al.*, 2016). Constructs encoding the predicted C-terminal domain of

TgMAF1RHa1 (residues 159–435) and TgMAF1RHb1 (residues 173–443: note, the C-terminal Met444, Leu445 and Asp446 residues are not included in the crystallization construct due to protein stability problems) (Genbank Accession numbers SCA78655 and AMN92247, respectively) were recombinantly produced in *Escherichia coli*, purified to homogeneity and crystallized for X-ray diffraction experiments (Fig. 2A). The structure of TgMAF1RHb1 was phased by bromide single wavelength anomalous dispersion and refined to a resolution of 1.60 Å. Overall, the structure is well ordered with clear electron density extending from the Ser173 through Ser443 and including two C-terminal

alanine residues derived from the expression vector. The 2.10 Å resolution structure of TgMAF1RHa1 was solved by molecular replacement using TgMAF1RHb1 as the search model with all three molecules in the asymmetric unit well-ordered. Despite possessing only 57% sequence identity within the C-terminal domain, structural overlays clearly showed that TgMAF1RHa1 and TgMAF1RHb1 adopt an overall similar architecture, with an RMSD of 0.6 Å over 240 C α atoms (Fig. 2B). Notably, these are the first structures of a MAF1 protein from any apicomplexan parasite.

Structural analysis of TgMAF1RHa1 and TgMAF1RHb1 revealed a compact, single domain with mixed α/β structure with a central, slightly curved eight-stranded Bsheet of mixed parallel and antiparallel strands bound on one side by a three-helical bundle and on the other side by a pair of helices (Fig. 2B). Intriguingly, a DALI (Holm and Rosenstrom, 2010) structural homology search revealed significant similarity to macroH2A nonhistone domains (also known as macro-domains) with the macro-domain from Archaeoglobulus fulgidus 1521 (Af1521) (Allen et al., 2003) identified as the most closely related structure (Z-score of 16; RMSD of 2.5 Å over 180 aligned $C\alpha$ positions) (Fig. 2C). A central feature of macro-domains is their ability to coordinate ADPribose (ADPr) and its derivatives through a surface cleft (Karras et al., 2005; Malet et al., 2009; Han et al., 2011; Barkauskaite et al., 2015) that is conserved in both TgMAF1RHa1 and TgMAF1RHb1. In fact, sequences of all apicomplexan MAF1 homologs mapped onto the TgMAF1RHb1 core structure revealed the cleft as one of the most evolutionary conserved regions, supporting that this cleft is performing an important function (Fig. 2D).

ADP-ribose forms a low affinity complex with TgMAF1RHa1 and TgMAF1RHb1

The striking resemblance to a canonical macro-domain and the presence of a well-conserved surface cleft led us to hypothesize that TgMAF1s may be able to accommodate ADPr or a similar small molecule. Further support for this hypothesis was based on the observation that the structural homolog Af1521 was able to form a stable complex with ADPr (Fig. 3A and B).

To investigate the ability of the TgMAF1 macrodomain to bind adenine nucleotide derivatives, we first determined co-structures of ADPr bound to TgMAF1RHa1 and TgMAF1RHb1 to 2.7 and 1.65 Å resolutions respectively. Stabilizing ADPr in the surface cleft is a Phe198 (TgMAF1RHb1) or Phe187 (TgMAF1RHa1) that stacks onto one side of the ADPr adenine ring and the side chains of Leu227 (TqMAF1RHb1) or Met216 (TqMAF1RHa1) that pack against the opposite side (Fig. 3B). In addition, the second phosphate fits into a specific pocket formed by Ile388 and Phe389 (ToMAF1RHb1) or His377 and Phe378 (TgMAF1RHa1) (Fig. 3B). Structural overlays revealed that residues in Af1521 known to be crucial for ADPr binding are not conserved in the TaMAF1 proteins; specifically, the strongly conserved Asp (labeled red in Fig. 3B) for selectivity of adenine-based nucleotides (Malet et al., 2009; Han et al., 2011) and the Asn (labeled red in Fig. 3B) shown to be critical for phosphatase activity on ADP-ribose-1-phosphate (Egloff et al., 2006; Malet et al., 2009) are not conserved (Fig. 3B). Thus, it appears that both ToMAF1RHa1 and TgMAF1RHb1 have lost key residues involved in coordinating ADPr suggesting, at minimum, a weaker binding affinity, which we next measured by isothermal titration calorimetry (ITC). Binding data were only obtained for TgMAF1RHa1, since the high salt required for TaMAF1RHb1 stability obscured complex formation. A $K_{\rm d}$ of approximately 400 μ M was measured for TgMAF1RHa1 (Fig. 3C), which is far weaker than the 130 nM K_d measured between ADPr and Af1521 (Karras et al., 2005). It is worth noting that poly(ADPr) or poly-A binding does not necessarily require ADPr to bind with high affinity to form a functional complex (Malet et al., 2009; Neuvonen and Ahola, 2009). Thus, we cannot rule out the possibility that TgMAF1RHa1 and/or TgMAF1RHb1 are capable of binding these anionic polymers in a biologically relevant setting. Nor can we rule out that TgMAF1RHb1 may be capable of binding other nucleotides or even oligonucleotides such as poly(A) or poly(ADP-ribose), as has been shown for other macro-domain containing proteins (Karras et al., 2005; Neuvonen and Ahola, 2009). However, the low affinity complexes observed here in both MAF1a and MAF1b paralog classes are consistent with the hypothesis that ADPr binding is not relevant to HMA.

Unique residues in the C-terminal helix of TgMAF1RHb1 are required for HMA

The structures of TgMAF1RHa1/b1 allowed us to identify additional residues for mutational studies by interrogating differences between the C- termini of both paralogs. We chose candidate residues by identifying residues that were (i) outward facing based on structural analysis and (ii) consistently polymorphic among all members of the 'A' and 'B' groups. We first mutated peripheral TgMAF1RHb1-specific β -sheet (residues 174–187) to their aligned sequence in TgMAF1RHb0. Additionally, we mutated the outward-facing Ser339 to the aligned TgMAF1RHa1 phenylalanine residue. Both


Fig. 3. Structural characterization of *Tg*MAF1RHa1/b1 reveals that ADP-ribose coordination by the macro-domains may be vestigial. A. Costructures of *Tg*MAF1RHa1, *Tg*MAF1RHb1 (grey surface) and ADP-ribose (ADPr) (wheat ball-and-stick coloured by element) and Af1521 (PDB ID: 1HJZ), highlighting the surface cleft of *Tg*MAF1RHa1 (left, coloured deep purple), *Tg*MAF1RHb1 (right, coloured limegreen) and Af1521 (left, coloured light blue).

B. The residues coordinating ADPr in Af1521, *Tg*MAF1RHa1 and *Tg*MAF1RHb1 are shown based on the overlay of *Tg*MAF1RHa1 (deep purple), *Tg*MAF1RHb1 (limegreen) and Af1521 (lightblue) with ADPr (shown as wheat stick coloured by element).

C. Representative ITC binding isotherm of ADPr titrating into TgMAF1RHa1. The ITC clearly shows a low affinity binding with a Kd of ~ 400 µM.

mutant constructs sufficiently conferred HMA when expressed in *Tg*Me49 parasites (Fig. 4A), indicating that these residues were not required for HMA.

We then focused on the 16 C-terminal residues of cloned MAF1b paralogs that are 94% similar to one another but harbor multiple polymorphisms that distinguish the A and B lineages (Fig. 4B). To investigate the significance of the C-terminus in MAF1-mediated HMA, we mutated the 16 C-terminal residues of TgMAF1RHb1 to those found in ToMAF1RHa1 to create a chimeric construct. Excitingly, the TgMAF1RHb1 16 C-terminal chimera was incapable of conferring HMA in TgME49, indicating a central role for the C-terminus in HMA (Fig. 4C). When we examined TgME49 expressing the TgMAF1Rhb1 16 C-terminal chimera, we found that, as for the WT TqMe49, there was no significant HMA based on quantification of % vacuole coverage using EM (Fig. 4D and E). The TgMAF1RHb1 16 C-terminal chimera shows similar vacuole coverage to an TgMe49 empty vector control further confirming the requirement of this region for HMA (Fig. 4E). We then investigated the sufficiency of the C-terminus of TgMAF1RHb1 in driving HMA. Using site-directed mutagenesis, we created a TgMAF1RHa1 chimeric construct with the 16 Cterminal residues of TgMAF1RHb1. The TgMAF1RHa1 16 C-terminal chimera did not drive HMA upon expression in TgMe49 parasites (Fig. 4F), showing that while the 16 C-terminal residues of TgMAF1RHb1 are necessary for HMA, when expressed in a Type II genetic background, they are not sufficient.

Three C-terminal residues in TgMAF1RHb1 are required for HMA

As described above and shown in Fig. 1A, the 16 C-terminal residues of TgMAF1RHb1 and TgMAF1RHa1 form the α 5 helix that is unique to each TgMAF1RHb1 and TgMAF1RHa1 paralog. To further interrogate this



Fig. 4. TgMAF1RHb1 16 C-terminal residues are required for HMA.

A. HFFs were infected with *Tg*Me49 parasites expressing an HA-tagged mutated *Tg*MAF1RHb1 isoform. Mutations were introduced using site-directed mutagenesis in an effort to disrupt key outward facing amino acids. Cells were fixed at 18 hpi and visualized using confocal microscopy. Immunofluorescence staining was performed with antibodies against the HA epitope tag and the mitochondrial protein, cytochrome *c* oxidase II (MTCO2). Symbols on mutation titles correspond to mutations in the structural overlay of both MAF1a and MAF1b generated in UCSF Chimera.

B. Alignment of the 16 C-terminal residues of MAF1 isoforms. Dark blue and white indicate 100 and 0% percent identity respectively. Alignments were visualized in JalView after alignment using Clustal-Omega. Yellow bars below alignment show residue conservation across MAF1 isoforms.

C. HFFs were infected with TgMe49 parasites expressing either a WT HA-TgMAF1RHb1 isoform or a TgMAF1THb1 16 C-terminal chimeric form. The C-terminal chimera contained TgMAF1RHb1 residues 1–430 and TgMAF1RHa1 residues 420–435. Cells were fixed and treated with the same conditions outlined in 4A.

D. HFFs were infected with isolated TgMe49 clones transfected with HA-TgMAF1RHb1, TgMAF1RHb1-C-term chimera or empty vector. Cells were fixed 18 hpi and processed for transmission electron microscopy. Mitochondria (M) are labeled.

E. Quantification of percent vacuole coverage, determined by electron microscopy. ****p < 0.0001, one-way ANOVA.

F. Normal rat kidney epithelial cells expressing RFP in the mitochondrial matrix (NRK mitoRFPs) were infected with *Tg*Me49 parasites expressing either a WT HA-*Tg*MAF1RHb1 isoform or a *Tg*MAF1RHa1 16 C-terminal chimeric form. The C-terminal chimera is *Tg*MAF1RHa1 residues 1–419 and *Tg*MAF1RHb1 residues 431–446. Cells were fixed 18 hpi and visualized using epi-fluorescent microscopy. Immunofluorescence staining was performed with antibodies against the HA epitope tag.



Fig. 5. Three residues in the C-terminus of TgMAF1RHb1 are required for HMA.

A. NRK mitoRFP cells were infected with *Tg*Me49 parasites expressing HA-*Tg*MAF1RHb1 16 C-terminal mutant variants. Cells were fixed 18 hpi and visualized using epi-fluorescent microscopy. Immunofluorescence staining was performed with antibodies against the HA epitope tag. B. *Tg*MAF1RHa1 and *Tg*MAF1RHb1 are highlighted in blue and red, respectively, which correspond to the color in the ribbon rendering of the C-terminal structures. Structure was visualized in UCSF chimera.

C. HFFs were infected with isolated *Tg*Me49 clones transfected with each of the HA-*Tg*MAF1RHb1 16 C-terminal mutants. Cells were fixed 18 hpi and processed for transmission electron microscopy. Mitochondria are labeled.

D. Quantification of percent vacuole coverage, determined by electron microscopy. ****p < 0.0001, one-way ANOVA ('all comparisons' means each comparison of T_g MAF1RHb1 C-terminal mutant and T_g MAF1RHb1 to T_g MAF1RHb1 is significant).

region, truncation mutations were made to the Cterminus of *Tg*MAF1RHb1 in an effort to abrogate HMA without disrupting proper MAF1 localization. Truncation of both the 16 and 8 C-terminal residues resulted in TgMAF1RHb1 products that did not confer HMA in TgMe49 parasites, confirming the requirement of these residues (Fig. 5A and C). The structural differences of both the TgMAF1RHb1 and TgMAF1RHa1 helices and



Fig. 6. TgMAF1RHb1 mutants bind to SAM50.

A. Immunoprecipitation of lysed HFFs infected with cloned *Tg*Me49: *Tg*MAF1RHb1 16 C-terminal mutants, *Tg*Me49:*Tg*MAF1RHb1 and *Tg*Me49:EV. Lysates were incubated with HA-conjugated beads and eluted with LDS sample buffer. Western blotting analysis was performed with the listed primary antibodies and HRP-conjugated secondary antibodies. Each 16 Cterminal mutant is able to bind to SAM50.

B. Densitometric input/eluate quantification of SAM50 western blot in (A) using ImageJ (NIH). Pulldowns of *Tg*MAF1RHb1 C-terminal mutant infections have been repeated three times. Pulldowns of *Tg*MAF1RHa1 infection was only performed once.

their opposing HMA phenotypes suggests residuespecific function within this region. Ten of the 16 C-terminal residues of this helix are polymorphic between the A and B paralogs, making it difficult to determine which residues to investigate based on primary sequence alone. However, when we examined the structure of the $\alpha 5$ helix, we identified a trio of basic residues unique to the C-terminus of ToMAF1RHa1, specifically Arg427, Lys428 and Lys430 (Fig. 5B). These are strikingly different than their uncharged counterparts in TgMAF1RHb1 (Ser438, Thr439 and Leu441) (Fig. 5B). To investigate the importance of these residues in HMA, we mutated the STL residues in TgMAF1RHb1 to RKK and this mutant was completely unable to mediate HMA when expressed in Type II T. gondii (Fig. 5A and C). Using electron microscopy, we found that the percentage of the vacuole with interacting mitochondria in parasites expressing the RKK mutant is nearly indistinguishable from wild-type Type II T. gondii (Fig. 5D). When we mutated each residue individually (Ser \rightarrow Arg, Thr \rightarrow Lys and Leu \rightarrow Lys), all three constructs could still mediate HMA when expressed in Type II T. gondii (Fig. 5A). Additionally, mutation of both the Ser438 and Leu441 to Arg427 and Lys430, which lie on the same face of the C-terminal alpha helix, mediated HMA when expressed in Type II parasites (Fig. 5A), suggesting the collective requirement of all three uncharged MAF1b residues (Ser438, Thr439 and Leu441) for HMA to occur.

TgMAF1RHb1 mutants retain binding to SAM50

*Tg*MAF1RHb1 has recently been shown to interact with the mitochondrial intermembrane space bridging (MIB)

drial membrane interacting, directly or indirectly, with TgMAF1RHb1 is SAM50 (Kelly et al., 2017). These data suggest that SAM50 might function as the protein TqMAF1RHb1 uses to anchor itself to the mitochondria. If interactions with SAM50 are the sole basis for mediating HMA, neither TqMAF1RHa1 nor our TqMAF1RHb1 with the chimeric C-terminus should interact with SAM50. To investigate the ability of each of the Cterminal mutants and TgMAF1RHa1 to interact with SAM50, we conducted co-immunoprecipitations using HA conjugated beads. Consistent with published data we found that HA pulldowns from TgME49 clones expressing N-terminally HA-tagged TgMAF1RHb1 coprecipitated SAM50, while cytosolic host protein (aTubulin) showed no evidence for association with TgMAF1RHb1 (Fig. 6A). Interestingly, however, we found that immunoprecipitations of TgMAF1RHa1, the TgMAF1RHb1 C-terminal truncation mutant and the TgMAF1RHb1:STL \rightarrow RKK mutant also specifically pulled down SAM50 (Fig. 6A). Together, these data demonstrate that the specificity of the interaction between MAF1 and SAM50 is not dependent on the 16 C-terminal residues and that MAF1-SAM50 interactions are not sufficient to mediate HMA.

complex which consists of proteins spanning both the

outer and inner mitochondrial membranes. One MIB component on the cytosolic face of the outer mitochon-

HMA-functional paralogs confer in vivo competitive advantage, but TgMAF1RHb1 C-terminal mutants do not

Previous work found that expression of TgMAF1RHb1 and not TgMAF1RHa1 in a Type II T. gondii strain

528 *M. L. Blank* et al.

provides a competitive advantage in an in vivo infection (Adomako-Ankomah et al., 2016). This growth advantage is not present during growth in vitro (Adomako-Ankomah et al., 2016). To test the in vivo selective advantage of expressing the C-terminal mutants, we performed in vivo competition assays by infecting mice with clonal lines expressing different HA-tagged WT and mutant TgMAF1RHa1 and TgMAF1RHb1 constructs with the same standard reference strain expressing only the empty vector (TgME49:EV). Mice were infected with total of 10⁵ tachyzoites and the initial percent of parasites expressing HA-tagged MAF1 was guantified by immunofluorescence assay (IFA). Consistent with previous results (Adomako-Ankomah et al., 2016), TgMAF1RHb1-expressing parasites competed effectively with the reference strain (Fig. 7A and B), while parasites expressing the TaMAF1RHb1 16 amino acid truncation (Fig. 7B), 16 amino acid C-terminal chimera (Fig. 7A and B) or the three amino acid C-terminal chimera (STL \rightarrow RKK; Fig. 7A and B), competed less effectively with the reference strain. In contrast, one of the single amino acid mutants (Leu441Lys), that is HMA⁽⁺⁾ (see Fig. 5A), had a competitive index similar to parasites expressing WT TqMAF1RHb1 (Fig. 7A, far right). It should be noted that in vivo competition assays are sensitive to parasite passage history, and we used a generic reference strain that was not passage matched to the strains expressing mutant MAF1b genes (although all of the HA-tagged lines were carefully passage matched). To further validate the competitive advantage of this mutant, a mixed, nonclonal population parasites Type 11 expressing TgMAF1RHof b1:Leu441Lys (HMA⁽⁺⁾) was injected into three Balb/C mice and the Leu441Lys expressing parasites were found to have a significant in vivo growth rate as compared to their WT TgMe49 counterparts (Fig. 7C). Additionally, TgMe49 parasites expressing TgMAF1RHb1: SL(438/441)RK outcompeted their passage-matched TgMe49:EV clone (Fig. 7D). These data show that the in vivo competitive advantage conferred by expressing TqMAF1RHb1 in Type II T. gondii is almost certainly due to its impact on HMA, rather than the introduction of an additional copy of MAF1b.

Discussion

The ability to closely associate with host cell mitochondria has evolved independently in multiple intracellular pathogens including *L. pneumophila*, *C. psittaci* and *T. gondii* (Jones *et al.*, 1972; Horwitz, 1983; Matsumoto *et al.*, 1991; Sinai *et al.*, 1997; Pernas *et al.*, 2014). However, in most organisms, the importance of this phenotype is unknown. In the case of *T. gondii*, the pathogen gene product required for this phenomenon has been identified as MAF1b, a gene present in multiple copies within a tandemly expanded locus bearing extensive intra-strain and species sequence variation (Adomako-Ankomah *et al.*, 2014, 2016). In previous work we have shown that this variation has phenotypic consequences both with respect to HMA and infectivity *in vivo* (Adomako-Ankomah *et al.*, 2016). In the present study, we have exploited MAF1 locus diversity by using comparative structural biology and genetic complementation to identify regions of MAF1b required to mediate HMA.

Both MAF1 paralogs harbor vestigial ADP-ribose binding domains in their C-termini

Paramount to our interrogation of the MAF1 locus was firstly characterizing two distinct MAF1 paralogs with opposing HMA phenotypes through crystallographic and in vitro mutational studies: TgMAF1RHa1 (TgMAF1RHa1; 'HMA⁽⁻⁾') and ToMAF1RHb1 (ToMAF1RHb1: 'HMA⁽⁺⁾') (Adomako-Ankomah et al., 2016). Given the fact that this domain binds ADPr with comparatively low affinity (Karras et al., 2005), it is likely that this domain is a pseudo ADPr binding domain. ADP-ribosylation is an essential post-translational modification (PTM) that regulates a wide range of cellular processes including host immune pathwavs (Karras et al., 2005). Pathogens such as the hepatitis E virus (HEV) and SARS evolved an antagonistic ADPr binding macro-domain, which reverses ADPribosylation events in order to subvert the host immune response (Li et al., 2016). Many poly-ADP-ribose polymerases (PARPs) members, which catalyze this PTM have been shown to undergo recurrent positive diversifying selection in mammals which suggests a host-pathogen molecular arms race. These systems explain a possible ancestral role for the ADPr binding domain of MAF1 in T. gondii (Daugherty et al., 2014; Li et al., 2016).

In addition to an expanded family of macro-domain containing proteins, the *T. gondii* genome harbors a large number of rhoptry pseudokinases that have lost catalytic activity. Multiple rhoptry pseudokinases are found within tandemly expanded gene clusters (e.g., ROP2/3/4 locus, Boothroyd and Dubremetz, 2008; Fox *et al.*, 2011, and ROP5, Reese and Boothroyd, 2011; Behnke *et al.*, 2011, 2012; Adomako-Ankomah *et al.*, 2014). MAF1 may represent a new locus, which has been modified from an existing protein domain for the purpose of manipulating the host cell. Interestingly, the repurposing of this locus likely occurred in the most recent common ancestor of *T. gon-dii, H. harmondi* and *N. caninum*, since all three parasite species harbor at least one MAF1 paralog, and based on sequence comparisons, they all appear to have retained

the pseudo-ADPr binding domain. To confirm whether the sequence comparison translated into structural conservation, we generated high confidence 3D models of *Hh*MAF1a/b and *Nc*MAF1b (Supporting Information Fig. S1). Despite a similar charge distribution and high sequence conservation of the surface cleft forming residues, MAF1 paralogs appear to have lost the ability for high affinity coordination of ADPr and its derivatives, consistent with our hypothesis that the cleft region may be a vestigial domain. The polymorphic 16 residue C-terminal region, however, exhibits a remarkably divergent surface charge, suggesting that the evolutionary pressure on the C- terminal region is comparatively more than the cleft region, consistent with the importance of this C-terminal helix in gaining a central role in mediating HMA.

Structure–function analyses suggest that the C-terminus of TgMAF1RHa1 has three residues that prevent HMA

We exploited sequence diversity across MAF1 paralog classes to ultimately determine that three residues in the C-terminus of MAF1b are necessary but not sufficient to mediate HMA. These data are consistent with previous studies of MAF1b, which found that C-terminally tagged MAF1b paralogs did not confer HMA in TgMe49 parasites (Pernas et al., 2014). Interestingly, the 16 C-terminal residues of the A and B paralogs that comprise the α 5 helix differ at 10 of the 16 amino acid positions within a given T. gondii strain and these differences are highly conserved across divergent T. gondii strains and between T. gondii and H. hammondi. Notably, the C-terminal a5 helices in TgMAF1RHa1 and TgMAF1RHb1 adopt slightly different positions with respect to the body of the macro-domain, which may be due to sequence polymorphisms. With respect to HMA, only three of the 10 polymorphic residues of TaMAF1RHb1 are required. We hypothesize that Ser438, Thr439 and Leu441 in MAF1b, which differ markedly from the structurally analogous Arg427, Lys428 and Lys430 residues in MAF1a, present an optimal surface enabling coordination of a yet unidentified protein partner that gives rise to the HMA phenotype. The basic patch in MAF1a may also support nonspecific molecular interactions with anionic biomolecules that effectively disrupt recruitment of HMA proteins. In either scenario, the significant differences in size and charge between the STL versus RKK residues appear to have profound effects on the ability of a given MAF1 paralog to drive HMA.

TgMAF1RHb1 mutants that do not mediate HMA still associate with members of the MICOS complex

*Tg*MAF1RHb1 exists primarily within the parasitophorous vacuole membrane (PVM) and has been found to

interact with members of the MICOS complex in cellular lysates (Kelly et al., 2017). The MICOS complex spans the mitochondrial inner membrane and is responsible for the structural integrity of the mitochondria (Harner et al., 2011; Kozjak-Pavlovic, 2017). Additionally, TgMAF1RHb1 pulls down SAM50 on the outer mitochondrial membrane, which interacts with the MICOS complex, forming the membrane inner bridge complex (MIB) (Kelly et al., 2017). Upon RNAi knockdown of SAM50 and MIC60, the ability of TgMAF1RHb1 to drive HMA was diminished (Kelly et al., 2017), suggesting that associations between TgMAF1RHb1 and the MICOS complex are required for HMA. In the present study, we found that all tested MAF1 paralogs (e.g., A and B) and HMA-deficient MAF1b mutants were capable of pulling down SAM50, although we did not determine precise binding affinities between the a and b paralogs and therefore do not know if their binding to SAM50 is equally avid. An exciting potential outcome from these data is that the ability to interact with host SAM50 may represent an ancestral function of MAF1 but that other interactions are necessary for effective HMA. The chimeric MAF1b/a constructs are perfect tools to identify the precise interactions necessary for this intriguing host cell manipulation phenotype.

MAF1b confers in vivo competitive advantage and replication rate

Parasites expressing HMA-driving MAF1b paralogs do confer a selective advantage during mouse infections (Adomako-Ankomah et al., 2016), but the direct link between HMA itself and this phenotype was lacking. In the present study, our results provide the most convincing evidence to date that HMA itself (rather than other effects mediated by ectopic expression of MAF1b) confers increased parasite replication and/or survival in vivo. The competitive index of the Leu \rightarrow Lys single mutant (which is HMA⁽⁺⁾) was clearly superior to that of the STL \rightarrow RKK triple mutant (which is HMA⁽⁻⁾; Fig. 7A and B). Arguably, loss of HMA function provides the parasites with a measurable disadvantage in vivo when competed with a WT TaMe49 strain continuously cultured in the lab. These data directly link HMA itself to increased in vivo parasite survival and/or growth. The selective advantage conferred by HMA is consistent with the fact that MAF1b paralogs show signs of positive, diversifying selection (defined previously in Adomako-Ankomah et al., 2016), while MAF1a paralogs are highly conserved between strains and across species (see Fig. 1A). Somewhat paradoxically, TgMAF1RHb1 expression in Type II parasites is also associated with an increased pro-inflammatory response in vitro (mouse embryonic



Days Post Infection

Days Post Infection

fibroblasts) and *in vivo*, including the differential regulation of key Type 1 IFNs and proinflammatory cytokines in mice (Pernas *et al.*, 2014). It is possible that increased cytokine production may either recruit more cells that are hospitable to *T. gondii* or block recruitment of cells that are more lethal to *T. gondii* (such as GR1⁺ macrophages; Dunay *et al.*, 2008; Gay *et al.*, 2016). It is also possible that the differential cytokine response is a direct result of a gene dosage effect of Type II parasites retaining their endogenous MAF1 locus and exogenously expressing an additional MAF1b paralog. This response is independent of the HMA phenotype and **Fig. 7.** HMA-functional paralog, T_g MAF1RHb1 confers *in vivo* competitive advantage but T_g MAF1RHb1 C-terminal mutants do not. A. Three mice per control or mutant were infected intraperitoneally (IP) with 50/50 mix of T_g Me49 parasites expressing either WT or C-terminal T_g MAF1RHb1 mutants and T_g Me49:EV parasites (i.e., 50% T_g Me49: T_g MAF1 16 C-terminal chimera vs. 50% T_g Me49 empty vector). HFFs were also infected with each input mixed population, fixed at 18 hpi and visualized utilizing epi-fluorescent microscopy. Immunofluorescence staining was performed with antibodies against the HA epitope tag. Following a five day *in vivo* infection, extracted peritoneal content was used to infect a monolayer of HFFs. Cells were fixed at 18 hpi and visualized utilizing epi-fluorescent microscopy. Immunofluorescence staining was performed with antibodies against the HA epitope tag. Both input (0 dpi) and output (5 dpi) populations were quantified by measuring the percent of MAF1-HA expressing parasites. **p = 0.0038, ****p < 0.0001 two-way ANOVA (Sidak test). B. Similar procedure as (A); however, input parasites populations were mixes of 25/75, 50/50 and 75/25 and only one mouse was infected for each of the mixes.

C. Similar procedure to (A) and (B). Three mice were IP infected with a natural mixed population of TgMe49:TgMAF1RHb1:L(441)K parasites. HFFs were infected with both input populations and peritoneal population after a five day infection. Cells were fixed and probed for parasites expressing HA-epitope tag by IFA (paired *t*-test, *p = 0.0174).

D. Similar procedure to (Å) and (B). Three mice were IP infected with a 50/50 mixture of TgMe49:EV and TgMe49:TgMAF1RHb1:SL(438/441)RK clones. HFFs were infected with both input populations and peritoneal population after a five day infection. Cells were fixed and probed for parasites expressing HA-epitope tag by IFA (paired *t*-test, **p = 0.0014).

represents another ancestral function that is shared in both MAF1a and MAF1b paralogs.

In summary, using structure–function analyses, we have identified three residues in *T. gondii* MAF1b that are required for MAF1b-mediated HMA and have definitively linked HMA to increased parasite proliferation *in vivo*. In the process, we have identified at least two functions associated with all MAF1 paralogs (ADP ribose coordination and association with the MICOS complex), which may represent the ancestral function of MAF1 prior to its neofunctionalization. This study has also enabled us to generate new MAF1 mutants that will serve as valuable reagents to probe the importance of HMA for *T. gondii* mediated host cell manipulation.

Experimental procedures

TgMAF1RHa1 and TgMAF1RHb1 cloning, protein production and purification

Constructs encoding the predicted C-terminal region of TgMAF1RHa1c (Genbank accession no KU761333) (reannotated TgMAF1RHb1; Ser173 to Ser443) and TgMAF1RHb1 (Genbank accession n. KU761342) (reannotated TgMAF1RHa1; Thr159 to Asp435) were cloned, produced and purified as previously described (Adomako-Ankomah *et al.*, 2016). Each protein was in a final buffer of HBS (20 mM Hepes pH 7.5, 150–300 mM NaCl) with 1% glycerol and 1 mM dithiothreitol.

Crystallization and data collection

Crystals of *Tg*MAF1RHb1 were initially identified in the PEG/ lon Screen (Hampton Research) using sitting drops at 295 K. The final, refined drops consisted of 1.2 μ l *Tg*MAF1RHb1 at 20 mg ml⁻¹ with 1.2 μ l of reservoir solution (0.2 M ammonium sulfate, 20% PEG3350) and were equilibrated against 120 μ l of reservoir solution. For phase determination, *Tg*MAF1RHb1 crystals were soaked in a final cryoprotectant of reservoir solution with 12.5% glycerol and 1 M NaBr for 3 min before flash cooling directly in liquid nitrogen. For co-crystallization with ADP-ribose (ADPr) (Sigma), *Tg*MAF1RHb1 was crystallized in the presence of 5 mM ADPr and the cryopreservation solution contained reservoir solution with 12.5% glycerol and 10 mM ADPr. Diffraction data were collected on beamline 08B1-1 at the Canadian Light Source (CLS) for bromide-derivatized crystals and on beamline 12-2 at the Stanford Synchrotron Radiation Lightsource (SSRL) for ADPr bound *Tg*MAF1RHb1.

Crystals of *Tg*MAF1RHa1 were initially identified in the Index screen (Hampton Research) using sitting drops at 295 K. The final, refined drops consisted of 1.0 μ l *Tg*MAF1RHa1 at 6.2 mg ml⁻¹ with 1.0 μ l of reservoir solution (0.9 M ammonium sulfate, 0.1 M Hepes pH 7.0, 0.5% PEG8000, 3% 2-methyl-2,4-pentanediol) and were equilibrated against 120 μ L of reservoir solution. Crystals were cryopreserved in 80% saturated lithium sulfate and flash cooled in liquid nitrogen. A subset of crystals was soaked with 10 mM ADPr prior to cryopreservation. Diffraction data for *Tg*MAF1RHa1 were collected on beamline 08ID-1 at the CLS and on beamline 11-1 at SSRL for ADPr bound *Tg*MAF1RHa1.

Data processing, structure solution and refinement

Diffraction data for TqMAF1 crystals were collected and processed to 1.60 Å (TgMAF1RHb1-Br), 1.65 Å (TgMAF1RHb1-ADPr), 2.10 Å (TgMAF1RHa1) and 2.70 Å (TgMAF1RHa1-ADPr) resolution using Imosflm (Battye et al., 2011), Scala (Evans, 2006) and Aimless (Evans and Murshudov, 2013) in the CCP4 suite of programs (Winn et al., 2011). The structure of TgMAF1RHb1 was phased by bromide single wavelength anomalous dispersion. A total of 18 Br sites were identified and refined using the ShelxC/ D/E pipeline (Sheldrick, 2010). High-quality phases were obtained following density modification in dm (Cowtan, 1994) and enabled building and registering of approximately 85% of the backbone using buccaneer (Cowtan, 2008). The TgMAF1RHb1-ADPr structure was solved by molecular replacement using the final refined TgMAF1RHb1 structure as the search model in PHASER (McCov et al., 2007), while the TgMAF1RHa1 structures were solved using a chainsaw trimmed model of TgMAF1RHb1 as the search model (Schwarzenbacher et al., 2004). For each structure, COOT (Emsley et al., 2010) was used for manual model building and selection of solvent atoms and the models were refined in Phenix.Refine (Afonine et al., 2012).

532 *M. L. Blank* et al.

Table 1. Data collection statistics.

	TgMAF1RHb1-Br	TgMAF1RHb1-ADPr	TgMAF1RHa1	TgMAF1Rha1-ADPr
A. Data collection statistics				
Space group	P212121	P212121	P21	P21
a, b, c (Å)	45.09, 62.11, 89.21	45.47, 62.36, 89.69	79.89, 49.67, 114.75	78.23, 49.52, 115.71
α, β, γ (°)	90, 90, 90	90, 90, 90	90, 96.09, 90	90, 96.63, 90
Wavelength (Å)	0.9195	0.9795	0.9794	0.9795
Resolution (Å)	45.09-1.60 (1.69-1.60)	51.20-1.65 (1.68-1.65)	48.86-2.10 (2.16-2.10)	27.40-2.70 (2.86-2.70)
Measured reflections	280,473 (26,900)	114,544 (5,631)	197,078 (14,313)	117,630 (16,227)
Unique reflections	33,786 (4,786)	29,065 (1,489)	51,862 (3,990)	23,134 (3,436)
Redundancy	8.3 (5.6)	3.9 (3.8)	3.8 (3.6)	5.1 (4.7)
Completeness (%)	99.8 (98.9)	93.4 (97.4)	98.5 (92.4)	94.4 (87.9)
<i>l</i> /σ(<i>l</i>)	12.7 (3.5)	7.6 (2.2)	11.5 (3.0)	11.6 (2.2)
R _{merge} (%)	10.3 (47.5)	9.4 (55.3)	8.0 (44.4)	9.0 (61.1)
B. Refinement statistics				
Resolution (Å)	44.60-1.60	40.56-1.65	48.86–2.10	27.40-2.70
$R_{\rm work}/R_{\rm free}$ (%)	17.0/21.0	20.5/22.8	21.2/24.4	23.3/28.3
Number of atoms				
Protein (A/B/C)	2057	2012	2114/2081/2099	2047/2005/1949
Solvent/Br/Na	257/11/3	105	159	16
Glycerol or sulfate	18	N/A	70	N/A
ADPribose	N/A	36	N/A	72
Average <i>B</i> -values (Å ²)				
Protein (A/B/C)	14.2	22.3	30.5/36.8/33.4	55.1/63.9/63.6
Solvent/Br/Na	24.0/26.9/32.9	28.4	31.5	42.6
Glycerol or sulfate	23.0	N/A	47.8	N/A
ADPribose	N/A	33.4	N/A	68.6
RMS deviation from ideality				
Bond lengths (Å)	0.008	0.012	0.003	0.003
Bond angles (°)	1.17	1.02	0.67	0.67
Ramachandran statistics (%))			
Most favoured	99.3	98.9	98.5	96.5
Allowed	0.7	1.1	1.5	3.5
Disallowed	0.0	0.0	0.0	0.0

Values in parentheses are for the highest resolution shell.

Complete structural validation was performed in Molprobity (Chen *et al.*, 2010). For each dataset, 5% of the reflections were set aside for calculation of $R_{\rm free}$. Data collection and refinement statistics are presented in Table 1.

The atomic coordinates and structure factors have been deposited in the Protein Data Bank under the following codes: TgMAF1RHb1-Br - 6BXR; TgMAF1RHb1-ADPr - 6BXW; TgMAF1RHa1 - 6BXS and TgMAF1RHa1-ADPr - 6BXT.

In silico homology modeling of HhMAF1a1/b1 and NcMAF1RHa1

The crystal structure of *Tg*MAF1RHa1 was used as a modeling template for *Hh*MAF1RHa1 and *Nc*MAF1RHa1 paralogs, while the structure of *Tg*MAF1RHb1 was used as the template for *Hh*MAF1RHb1. The sequence identity between target and template was 40% or greater for all the MAF1 paralogs. Using Modeller 9v18 (Webb and Sali, 2014), 10 models for each MAF1 paralog was generated and the best model chosen based on the low value of normalized discrete optimized protein energy (DOPE). The assessment of the final model was carried out with Ramachandran statistics (Lovell, Davis, Arendal, de Bakker, Word, Prisant, Richardson, Richardson, 2002), QMEAN (Benkert *et al.*,

2008) and ProSA (Wiederstein and Sippl, 2007) (Supporting Information Table S1).

Cell maintenance and parasite infection

*Tg*Me49 in these experiments were regularly passed in human foreskin fibroblasts (HFFs) and incubated at 37°C in 5% CO₂. NRK mito-RFP cells were a kind gift from Jennifer Lippincott-Schwartz (NIH, Bethesda, MD) (Mitra and Lippincott-Schwartz, 2010). Both cell types were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 50 μ g ml⁻¹ of penicillin and streptomycin, 10% FBS and 2 mM glutamine (cDMEM).

Expression of MAF1 mutants and transgenic parasites

Parental plasmid used for cloning all *Tg*MAF1RHb1 constructs contains the *HXGPRT* gene. *Tg*MAF1RHb1 proline–alanine mutations were constructed using short overlap extension (SOE) PCR. *Tg*MAF1RHb1 and *Tg*MAF1RHa1 C-terminal mutants were generated using a site-directed mutagenesis kit (NEB Q5 site-directed mutagenesis). All constructs were confirmed by sanger sequencing methods using *Tg*MAF1RHb1 specific primers (Genewiz). The constructs

contain the endogenous TgMAF1RHb1 promoter followed by the start codon, signal peptide, N-terminal hemagglutinin (HA) epitope tag and end at the stop codon. Transgenic lines were generated using TgMe49AHXGPRT:Luciferase parasites that were transfected with 55 μ g of DNA linearized with HindIII. A T25 flask of TgMe49AHXGPRT:Luciferase parasites was scraped and passed through a 25 and 27 G needle followed by centrifugation for 10 min at 800 \times g. A total of 2 \times 10⁷ parasites were re-suspended in Cytomix (120 mM KCl; 0.15 mM CaCl₂; 10 mM KPO₄; 25 mM Hepes, 2 mM EDTA, 5 mM MgCl₂; pH 7.6), GSH and ATP. Parasites were electroporated with 1.6 kV and 25 µF. Following 24 h of growth in cDMEM, parasites were selected with mycophenolic acid (MPA)/xanthine. Selected populations were then cloned via limited serial dilution in a 96-well plate. Cloned parasites were confirmed through immunofluorescence assays (IFA) by probing for HA epitope tag.

Immunofluorescence assays and microscopy

HFFs and NRK mito-RFP cells were grown to 100 and 60% confluency, respectively, on 0.7 cm² eight-well glass chamber slide system (ThermoFisher Scientific) in cDMEM. Monolavers were infected at an MOI of 1 with transgenic parasites. Cells were fixed at 18 hpi with 4% paraformaldehyde for 15 min and blocked/permeabilized with blocking buffer (5% BSA, 0.1% Triton X-100, PBS). HFFs and NRK mito-RFP cells were then probed with anti-HA rat monoclonal antibody (3F10 clone; Roche) diluted to 0.1 μ g ml⁻¹ in blocking buffer (see above) for 1 h at room temperature while shaking. HFFs were also incubated in anti-MTCO2 mouse monoclonal antibody and cells were washed with PBS. HFFs were incubated in 488 goat antirat and 594 goat antimouse secondary antibody (Life Technologies Alexa Fluor H + L) for 1 h at room temperature while shaking, followed by PBS washes. NRK mito-RFP cells were incubated in 488 goat antirat secondary antibody for 1 hour followed by PBS washes. HFFs and NRK mito-RFP were then mounted in Vectashield mounting media (Vector Laboratories) and sealed with cover glass. Slides were visualized using both confocal and epifluorescence microscopy. Images were taken of the three channels: 488 (anti-HA), 594 (anti-MTCO2 and mito-RFP) and DIC/phase. Images were cropped and merged using ImageJ (NIH).

MAF1 paralog alignments and C-terminal structural views

All MAF1 paralog sequences were obtained from GenBank (NCBI accession numbers: SCA78755.1, ANN02899.1, AMN92255.1, AMN92254.1, AMN92252.1, AMN92247.1, AMN92246.1, AMN92253.1, AMN92250.1, AMN92249.1 and AMN92248.1) and aligned by percent identity using Clustal Omega. Alignment was visualized using JalView (Waterhouse *et al.*, 2009). *Tg*MAF1RHb1 and *Tg*MAF1RHa1 primary amino acid sequences were visualized using the UCSF chimera software (Pettersen *et al.*, 2004; Meng *et al.*, 2006).

Structure of T. gondii MAF1 determines ancestral function 533

HFFs were infected with TqMAF1RHb1 C-terminal mutants. At 18 hpi, cells were fixed with 2.5% glutaraldehyde in PBS for 1 h at room temperature, washed three times with PBS for 10 min, postfixed for 1 h at 4°C in 1% OsO₄ with 1% potassium ferricyanide and washed three times with PBS. Samples were then dehydrated in a graded series of alcohol for ten minutes with three changes in 100% ethanol for 15 min and changed three times in epon for 1 h each. Following the removal of epon, samples were covered with resin and polymerized at 37°C overnight and then 48 h at 60°C (protocol: Center for Biological Imagining [CBI], University of Pittsburgh, Pittsburgh, PA, USA). Samples were cross sectioned and processed by the CBI. Five vacuoles containing two parasites were imaged for each of the infections. Vacuoles were traced in ImageJ, and the percentage of the total distance around the vacuole in direct contact with the host mitochondria was quantified for each of the mutants and controls (Schneider et al., 2012).

Immunoprecipitation and immunoblotting

HFFs were infected with cloned TgMe49 parasites expressing a TqMAF1RHb1 C-terminal mutant, TqMe49:Tq-MAF1RHb1, TqMe49:Empty Vector or TgMe49:TgMAF1RHa1 at an MOI of 2. Cell were lysed in IP lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% IGE-PAL CA-630, 0.05% Tween 20) and treated with complete protease inhibitors (Roche) on ice. The insoluble fraction was pelleted at 700 \times g for 10 min at 4°C, and the soluble fraction was incubated with Pierce anti-HA magnetic beads (Thermo Scientific) for 2 h at room temperature using a rotator. Beads were washed five times with IP lysis buffer and eluted by boiling in LDS sample buffer (Thermo Scientific). Both input and eluate fractions were resolved on 10% SDS-PAGE gel and transferred to nitrocellulose membrane. Membranes were blocked in 5% BSA in PBST and probed with primary antibodies to HA, SAM50 and tubulin followed by goat horse radish peroxidase (HRP)-conjugated secondary antibodies. Bands were visualized with SuperSignal West Pico chemiluminescent substrates (Thermo Scientific). Antibodies used for these experiments: anti-HA highaffinity rat monoclonal antibody (clone 3F10) (Roche), goat antirat IgG H&L HRP (Abcam), anti-SAMM50 antibody (Abcam), goat antirabbit IgG HRP (Southern Biotech) and goat antimouse IgG HRP (Southern Biotech).

In vivo competition assay

Mice were 12-week-old Balb/C female mice (Jackson Labs). Using the same mutant and control parasite clones previously listed, we created a 1:1 mix of TgMe49:EV and TgMe49:TgMAF1RHb1, TgMe49:EV and TgMAF1RHb1 STL(438–441)RKK and TgMe49:EV and TgMAF1RHb1 L(441)K. TgME49:EV served as a baseline control and was not passage matched to the experimental strain. Three mice were intraperitoneally (IP) infected with 10⁵ tachyzoites for each of the mixes allowing us to have three biological replicates

534 *M. L. Blank* et al.

for each treatment group. Coverslips with confluent HFFs were infected with the same mixed population preparations and probed for HA tag to quantify the input percentage of each mix. Parasite burden was measured daily over the course of the five day infection using in *vivo* bioluminescence imaging (Walzer *et al.*, 2013). On day 6, each mouse was sacrificed and a peritoneal lavage was performed with PBS. A fraction of the peritoneal content was used to infect a confluent monolayer of HFFs, fixed at 18 hpi and probed for HA tag for output percentage quantification.

Ethics statement

Animal experiments were conducted according to the guidelines of the American Veterinary Medical Association. Accordingly, all euthanasia of animals was carried out using controlled exposure to CO_2 . All animal protocols were approved by the local Institutional Animal Care Committee at the University of Pittsburgh under IACUC protocol #12010130.

Acknowledgements

The authors would like to thank the technical support staff at the Stanford Synchrotron Radiation Lightsource, Canadian Light Source, and the University of Pittsburgh Center for Biological Imaging. This work was supported by Canadian Institutes of Health Research grant 148596 to MJB, National Institutes of Health (NIH) grant AI114655 to JPB and AI73756 to JCB and National Science Foundation Graduate Student Research Fellowship to LFP. MJB gratefully acknowledges the Canada Research Chair program for salary support. We would also like to thank Sarah Sokol, Rachel Coombs, Sheen Wong and Elizabeth Rudzki for editing this article.

Author contributions

MLB, MLP, RR, EDE, YA-A, LFP, JCB, MJB and JPB conceived and designed the experiments. MLB, MLP, RR, CJP, EDE, YA-A, LFP and SDW performed the experiments. MLB, MLP, RR, MJB and JPB analyzed the data and wrote the article.

References

- Adomako-Ankomah, Y., English, E.D., Danielson, J.J., Pernas, L.F., Parker, M.L., Boulanger, M.J., *et al.* (2016) Host mitochondrial association evolved in the human parasite *Toxoplasma gondii* via neofunctionalization of a gene duplicate. *Genetics* **203**: 283–298.
- Adomako-Ankomah, Y., Wier, G.M., Borges, A.L., Wand, H.E., and Boyle, J.P. (2014) Differential locus expansion distinguishes Toxoplasmatinae species and closely related strains of *Toxoplasma gondii*. *MBio* 5: e01003-13.
- Afonine, P.V., Grosse-Kunstleve, R.W., Echols, N., Headd, J.J., Moriarty, N.W., Mustyakimov, M., *et al.* (2012) Towards automated crystallographic structure refinement with phenix.refine. *Acta Crystallogr D: Biol Crystallogr* **68**: 352–367.

- Allen, M.D., Buckle, A.M., Cordell, S.C., Lowe, J., and Bycroft, M. (2003) The crystal structure of AF1521 a protein from *Archaeoglobus fulgidus* with homology to the non-histone domain of macroH2A. J Mol Biol **330**: 503–511.
- Ashkenazy, H., Erez, E., Martz, E., Pupko, T., and Ben-Tal, N. (2010) ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. *Nucleic Acids Res* 38: W529–WW33.
- Barkauskaite, E., Jankevicius, G., and Ahel, I. (2015) Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADPribosylation. *Mol Cell* 58: 935–946.
- Battye, T.G., Kontogiannis, L., Johnson, O., Powell, H.R., and Leslie, A.G. (2011) iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. *Acta Crystallogr D: Biol Crystallogr* **67**: 271–281.
- Behnke, M.S., Fentress, S.J., Mashayekhi, M., Li, L.X., Taylor, G.A., and Sibley, L.D. (2012) The polymorphic pseudokinase ROP5 controls virulence in *Toxoplasma* gondii by regulating the active kinase ROP18. *PLoS Pathog* 8: e1002992.
- Behnke, M.S., Khan, A., Wootton, J.C., Dubey, J.P., Tang, K., and Sibley, L.D. (2011) Virulence differences in *Toxoplasma* mediated by amplification of a family of polymorphic pseudokinases. *Proc Natl Acad Sci USA* **108**: 9631–9636.
- Benkert, P., Tosatto, S.C., and Schomburg, D. (2008) QMEAN: a comprehensive scoring function for model quality assessment. *Proteins Struct Funct Bioinformatics* **71**: 261–277.
- Boothroyd, J.C., and Dubremetz, J.F. (2008) Kiss and spit: the dual roles of *Toxoplasma rhoptries*. *Nat Rev Microbiol* **6**: 79–88.
- Chen, V.B., Arendall, W.B., 3rd, Headd, J.J., Keedy, D.A., Immormino, R.M., Kapral, G.J., *et al.* (2010) MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr D: Biol Crystallogr* **66**: 12–21.
- Cowtan, K. (1994) dm: an automated procedure for phase improvement by density modification. *Joint CCP4 ESF EACBM Newsletter Protein Crystallogr* **31**: 34–38.
- Cowtan, K. (2008) Fitting molecular fragments into electron density. Acta Crystallogr D: Biol Crystallogr 64: 83–89.
- Daugherty, M.D., Young, J.M., Kerns, J.A., and Malik, H.S. (2014) Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts. *PLoS Genet* **10**: e1004403.
- Dunay, I.R., Damatta, R.A., Fux, B., Presti, R., Greco, S., Colonna, M., *et al.* (2008) Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen *Toxoplasma gondii. Immunity* **29**: 306–317.
- Egloff, M.P., Malet, H., Putics, A., Heinonen, M., Dutartre, H., Frangeul, A., *et al.* (2006) Structural and functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains. *J Virol* **80**: 8493–8502.
- Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr D: Biol Crystallogr 66: 486–501.
- Evans, P.R. (2006) Scaling and assessment of data quality. *Acta Cryst* **62**: 72–82.
- Evans, P.R., and Murshudov, G.N. (2013) How good are my data and what is the resolution? *Acta Crystallogr D: Biol Crystallogr* **69**: 1204–1214.

- Fox, B.A., Falla, A., Rommereim, L.M., Tomita, T., Gigley, J.P., Mercier, C., *et al.* (2011) Type II *Toxoplasma gondii* KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection. *Eukaryot Cell* **10**: 1193–1206.
- Gay, G., Braun, L., Brenier-Pinchart, M.P., Vollaire, J., Josserand, V., Bertini, R.L., *et al.* (2016) *Toxoplasma gondii* TgIST co-opts host chromatin repressors dampening STAT1-dependent gene regulation and IFN-gammamediated host defenses. *J Exp Med* **213**: 1779–1798.
- Han, W., Li, X., and Fu, X. (2011) The macro domain protein family: structure, functions, and their potential therapeutic implications. *Mutat Res* 727: 86–103.
- Harner, M., Korner, C., Walther, D., Mokranjac, D., Kaesmacher, J., Welsch, U., *et al.* (2011) The mitochondrial contact site complex, a determinant of mitochondrial architecture. *EMBO J* **30**: 4356–4370.
- Holm, L., and Rosenstrom, P. (2010) Dali server: conservation mapping in 3D. *Nucleic Acids Res* 38: W545–W549.
 (Web Server issue):
- Horwitz, M.A. (1983) Formation of a novel phagosome by the Legionnaires' disease bacterium (*Legionella pneumophila*) in human monocytes. *J Exp Med* **158**: 1319–1331.
- Jones, T.C., Yeh, S., and Hirsch, J. (1972) The interaction between *Toxoplasma gondii* and mammalian cells. *J Exp Med* **136**: 1157–1172.
- Karras, G.I., Kustatscher, G., Buhecha, H.R., Allen, M.D., Pugieux, C., Sait, F., *et al.* (2005) The macro domain is an ADP-ribose binding module. *EMBO J* 24: 1911–1920.
- Kelly, F.D., Wei, B.M., Cygan, A.M., Parker, M.L., Boulanger, M.J., and Boothroyd, J.C. (2017) *Toxoplasma gondii* MAF1b binds the host cell MIB complex to mediate mitochondrial association. *mSphere* 2: e00183-17.
- Kozjak-Pavlovic, V. (2017) The MICOS complex of human mitochondria. *Cell Tissue Res* 367: 83–93.
- Lovell, S.C., Davis, I.W., Arendall, W.B. III., de Bakker, P.I.W., Word, J.M., Prisant, M.G., *et al.* (2002) Structure validation by Calpha geometry: phi, psi and Cbeta deviation. *Proteins Struct Funct Genet* **50**: 437–450.
- Li, C., Debing, Y., Jankevicius, G., Neyts, J., Ahel, I., Coutard, B., *et al.* (2016) Viral macro domains reverse protein ADP-ribosylation. *J Virol* **90**: 8478–8486.
- Malet, H., Coutard, B., Jamal, S., Dutartre, H., Papageorgiou, N., Neuvonen, M., *et al.* (2009) The crystal structures of Chikungunya and Venezuelan equine encephalitis virus nsP3 macro domains define a conserved adenosine binding pocket. *J Virol* **83**: 6534–6545.
- Matsumoto, A., Bessho, H., Uehira, K., and Suda, T. (1991) Morphological studies of the association of mitochondria with chlamydial inclusions and the fusion of chlamydial inclusions. *J Electron Microsc* **40**: 356–363.
- McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007) Phaser crystallographic software. *J Appl Crystallogr* **40**: 658–674.
- Meng, E.C., Pettersen, E.F., Couch, G.S., Huang, C.C., and Ferrin, T.E. (2006) Tools for integrated sequence-structure analysis with UCSF Chimera. *BMC Bioinformatics* **7**: 339.
- Mitra, K., and Lippincott-Schwartz, J. (2010) Analysis of mitochondrial dynamics and functions using imaging approaches. *Curr Protoc Cell Biol* **Chapter 4**: Unit 4 25 1-1.

- Neuvonen, M., and Ahola, T. (2009) Differential activities of cellular and viral macro domain proteins in binding of ADP-ribose metabolites. *J Mol Biol* **385**: 212–225.
- Pernas, L., Adomako-Ankomah, Y., Shastri, A.J., Ewald, S.E., Treeck, M., Boyle, J.P., *et al.* (2014) *Toxoplasma* effector MAF1 mediates recruitment of host mitochondria and impacts the host response. *PLoS Biol* **12**: e1001845.
- Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., *et al.* (2004) UCSF chimera – a visualization system for exploratory research and analysis. *J Comput Chem* **25**: 1605–1612.
- Reese, M.L., and Boothroyd, J.C. (2011) A conserved noncanonical motif in the pseudoactive site of the ROP5 pseudokinase domain mediates its effect on *Toxoplasma* virulence. *J Biol Chem* **286**: 29366–29375.
- Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012) NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 9: 671–675.
- Schwarzenbacher, R., Godzik, A., Grzechnik, S.K., and Jaroszewski, L. (2004) The importance of alignment accuracy for molecular replacement. *Acta Cryst* **60**: 1229–1236.
- Sheldrick, G.M. (2010) Experimental phasing with SHELXC/D/E: combining chain tracing with density modification. *Acta Crystallogr D: Biol Crystallogr* **66**: 479–485.
- Sinai, A.P., Webster, P., and Joiner, K.A. (1997) Association of host cell endoplasmic reticulum and mitochondria with the *Toxoplasma gondii* parasitophorous vacuole membrane: a high affinity interaction. *J Cell Sci* **110**: 2117–2128.
- Treeck, M., Sanders, J.L., Elias, J.E., and Boothroyd, J.C. (2011) The phosphoproteomes of *Plasmodium falciparum* and *Toxoplasma gondii* reveal unusual adaptations within and beyond the parasites' boundaries. *Cell Host Microbe* **10**: 410–419.
- Walzer, K.A., Adomako-Ankomah, Y., Dam, R.A., Herrmann, D.C., Schares, G., Dubey, J.P., *et al.* (2013) *Hammondia hammondi*, an avirulent relative of *Toxoplasma gondii*, has functional orthologs of known *T. gondii* virulence genes. *Proc Natl Acad Sci USA* **110**: 7446–7451.
- Waterhouse, A.M., Procter, J.B., Martin, D.M., Clamp, M., and Barton, G.J. (2009) Jalview Version 2 – a multiple sequence alignment editor and analysis workbench. *Bioinformatics* **25**: 1189–1191.
- Webb, B., and Sali, A. (2014) Protein structure modeling with MODELLER. *Protein Struct Predict* **426**: 145–159.
- Wiederstein, M., and Sippl, M.J. (2007) ProSA-web: interactive web service for the recognition of errors in threedimensional structures of proteins. *Nucleic Acids Res* 35: W407–WW10.
- Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., *et al.* (2011) Overview of the CCP4 suite and current developments. *Acta Crystallogr D: Biol Crystallogr* **67**: 235–242.

Supporting information

Additional supporting information may be found in the online version of this article at the publisher's web-site.